Navigation Links
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Date:12/21/2007

PRINCETON, N.J., Dec. 21 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. announced today that the U.S. Food and Drug Administration has accepted a new drug application (NDA) for the company's investigational oral once-daily medication tolvaptan, a selective V2-vasopressin receptor antagonist, for two indications: treatment of adults with worsening heart failure and treatment of hyponatremia.(1) These indications are based on data from three phase 3 pivotal trials.(2)

OPDC was established in 2007 by Otsuka America, Inc. (OAI). OPDC is wholly owned by OAI, which is the holding company for Otsuka Pharmaceutical Co., Ltd. (OPC) interests in the U.S. OAI is wholly owned by OPC.

Tolvaptan is a novel, investigational small molecule designed to be an antagonist of the vasopressin V2 receptor, which plays a role in the kidney's regulation of fluid excretion. The majority of patients hospitalized for worsening heart failure have edema or excess body fluid, which is treated with diuretics to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of electrolyte-free water. In clinical trials, the most common adverse reactions in patients with worsening heart failure (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth and polyuria. In patients with hyponatremia, the most common adverse reactions in clinical trials (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth, asthenia, constipation, pollakiuria and hyperglycemia. The most serious adverse events were cardiogenic shock (1.7% in patients receiving tolvaptan vs. 1.2% of patients receiving placebo), pulmonary embolism (1.3% in patients receiving tolvaptan vs. 0.8% for patients receiving placebo,) and gout (4.7% in patients rece
'/>"/>

SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
(Date:8/29/2014)... York (PRWEB) August 29, 2014 ... at $5.6 billion in 2019. It is expected ... 2013 to 2019, and was valued at $1.8 ... published by Transparency Market Research. , For more ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... leading nonprofit organizations - the American Botanical Council ... University of Mississippi,s National Center for Natural Products ... to educate members of the herbal and dietary ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) ...
... SAN FRANCISCO, Nov. 2, 2011 Jennerex, Inc., a ... commercialization of first-in-class targeted oncolytic products for cancer, today ... clinical trial in advanced liver cancer patients will be ... Annual Meeting of the American Association for the Study ...
... 2, 2011 - Vaginal Self-collection for ... Increases Screening Coverage and is More Sensitive than Pap Smear ... Promising findings published today online in the ... trial undertaken by public health authorities in Mexico to investigate ...
Cached Biology Technology:Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 2Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 3Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 4Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 5Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 6Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 2Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 3Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 2Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 3Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 5
(Date:8/29/2014)... In a cell,s nucleus, chromosomal DNA is tightly ... amalgam biologists call chromatin. Until about two decades ... the mere packing material around which the glamorous ... developed a greater appreciation for how DNA/histone interactions ... multiple research institutions studying the sequence of the ...
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... Society of America (ESA) is pleased to announce the ... of the Society. Honorary Membership acknowledges those who have ... involvement in the affairs of the Society that has ... selected by the ESA Governing Board and then voted ... honored at the Awards Ceremony at Entomology 2014, ESA,s ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... In experiments with mice, researchers have found that eliminating ... the development of pain-sensing neurons knocks out the animals' ... that outlasts the injury and is associated with nerve ... in the gene, called Runx1, also showed lack of ...
... from Scripps Research; the Genomics Research Center, Academia Sinica, ... published today in the journal Chemistry and Biology (Vol. ... Ernest W. Hahn Chair in Chemistry at the Skaggs ... lab heading the study. He said the new finding ...
... Pacific Islands nation has distinguished itself on the global ... creating the third largest marine protected area in the ... most pristine coral reefs. , Martin Puta Tofinga, Minister ... of Kiribati, announced the establishment of the Phoenix Islands ...
Cached Biology News:Master genetic switch found for chronic pain 2Enzyme inhibitors block replication of SARS virus 2Pacific Islands paradise protected 2Pacific Islands paradise protected 3
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Biology Products: